Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record.

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

Open access
Martín, Miguel, Seguí, Miguel A., Antón, Antonio, Ruiz, Amparo, Ramos, Manuel, Adrover, Encarna, Aranda, Ignacio, Rodríguez-Lescure, Alvaro, Große, Regina, Calvo, Lourdes, Barnadas, Agustí, Isla, Dolores, Martinez del Prado, Purificación, Ruiz Borrego, Manuel, Zaluski, Jerzy, Arcusa, Angels, Muñoz, Montserrat, López Vega, José M., Mel, José R., Munarriz, Blanca, Llorca, Cristina, Jara, Carlos, Alba, Emilio, Florián, Jesús, Li, Junfang, López García-Asenjo, José A., Sáez, Amparo, Rios, María José, Almenar, Sergio, Peiró, Gloria, Lluch, Ana · 2010 · New England Journal of Medicine

Abstract

BACKGROUND: A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined. METHODS: We randomly assigned 1060 women with axillary-node-negative breast cancer and at least one high-risk factor for recurrence (according to the 1998 St. Gallen criteria) to treatment with TAC or FAC every 3 weeks for six cycles after surgery. The primary end point was disease-free survival after at least 5 years of follow-up. Secondary end points included overall survival and toxicity. RESULTS: At a median follow-up of 77 months, the proportion of patients alive and disease-free was higher among the 539 women in the TAC group (87.8%) than among the 521 women in the FAC group (81.8%), representing a 32% reduction in the risk of recurrence with TAC (hazard ratio, 0.68; 95% confidence interval [CI], 0.49 to 0.93; P=0.01 by the log-rank test). This benefit was consistent, regardless of hormone-receptor status, menopausal status, or number of high-risk factors. The difference in survival rates (TAC, 95.2%; FAC, 93.5%) was not significant (hazard ratio, 0.76; 95% CI, 0.45 to 1.26); however, the number of events was small (TAC, 26; FAC, 34). Rates of grade 3 or 4 adverse events were 28.2% with TAC and 17.0% with FAC (P<0.001). Toxicity associated with TAC was diminished when primary prophylaxis with granulocyte colony-stimulating factor was provided. CONCLUSIONS: As compared with adjuvant FAC, adjuvant TAC improved the rate of disease-free survival among women with high-risk, node-negative breast cancer. (Funded by GEICAM and Sanofi-Aventis; ClinicalTrials.gov number, NCT00121992.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0910320

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Martín, M., Seguí, M. A., Antón, A., Ruiz, A., Ramos, M., Adrover, E., Aranda, I., Rodríguez-Lescure, A., Große, R., Calvo, L., Barnadas, A., Isla, D., Martinez del Prado, P., Ruiz Borrego, M., Zaluski, J., Arcusa, A., Muñoz, M., López Vega, J. M., Mel, J. R., Munarriz, B., Llorca, C., Jara, C., Alba, E., Florián, J., Li, J., López García-Asenjo, J. A., Sáez, A., Rios, M. J., Almenar, S., Peiró, G., & Lluch, A.
Venue
New England Journal of Medicine
Published
2010-12-02
Volume
363
Issue
23
Pages
2200-2210
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2084370697
Cited by
209
References
0
FWCI
6.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.